x

Posted 24 January, 2024

Apollo Medical Holdings, Inc. appointed new CEO

CEO Change detected for ticker Nasdaq:AMEH in a 8-K filed on 24 January, 2024.


  · Brandon Sim, previously Co-Chief Executive Officer, was appointed Chief Executive Officer and President; and  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of Apollo Medical Holdings, Inc.
Health Care/Life Sciences • Healthcare Provision
Apollo Medical Holdings, Inc. is a physician-centric, technology-powered, risk-bearing healthcare management company, which engages in the provision of care coordination services and a healthcare delivery platform. The company was founded on November 1, 1985 and is headquartered in Alhambra, CA.
Market Cap
N/A
View Company Details
Apollo Medical Holdings, Inc. by TradingView
Relevant filing section
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. 


On January 24, 2024, Apollo Medical Holdings, Inc. (the "Company") announced the following executive appointments, which were approved by the Board of Directors (the "Board") on January 19, 2024, effective immediately:


· Thomas S. Lam, M.D., M.P.H., previously Co-Chief Executive Officer and President and a director, was appointed Vice Chairman of the Board; 


· Brandon Sim, previously Co-Chief Executive Officer, was appointed Chief Executive Officer and President; and 


· Chandan Basho, previously Chief Financial Officer and Chief Strategy Officer, was appointed Chief Financial Officer and Chief Operating Officer. 


Each of Dr. Lam, Mr. Sim and Mr. Basho's biographical information is included under the heading "Board of Directors and Executive Officers" in the Company's Definitive Proxy Statement for its 2023 Annual Meeting of Stockholders filed with the Securities and Exchange Commission on April 28, 2023 (the "Proxy Statement") and incorporated herein by reference. There were no changes to the Company's compensation arrangements with Dr. Lam, Mr. Sim or Mr. Basho as a result of the foregoing appointments.


There is no arrangement or understanding between any of Dr. Lam, Mr. Sim or Mr. Basho or any other person pursuant to which he was selected as an officer of the Company, and there are no family relationships between any of Dr. Lam, Mr. Sim or Mr. Basho and any of the Company's directors or executive officers, except that Mr. Sim is the son of Kenneth Sim, M.D., the Company's Executive Chairman. There are no transactions to which the Company is a party and in which any of Dr. Lam, Mr. Sim or Mr. Basho has a direct or indirect material interest that would be required to be disclosed under Item 404(a) of Regulation S-K, other than those described under the heading "Certain Related Person Transactions" in the Proxy Statement, which information is incorporated herein by reference.